Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Jazz Pharmaceuticals PLC    JAZZ   IE00B4Q5ZN47

JAZZ PHARMACEUTICALS PLC (JAZZ)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
174.81(c) 175.6(c) 176.05(c) 177.11(c) 176.49(c) Last
271 744 251 186 320 012 424 318 294 879 Volume
-0.66% +0.45% +0.26% +0.60% -0.35% Change
More quotes
Financials (USD)
Sales 2018 1 903 M
EBIT 2018 1 019 M
Net income 2018 439 M
Debt 2018 560 M
Yield 2018 -
Sales 2019 2 144 M
EBIT 2019 1 164 M
Net income 2019 613 M
Finance 2019 304 M
Yield 2019 -
P/E ratio 2018 25,13
P/E ratio 2019 18,03
EV / Sales2018 5,90x
EV / Sales2019 4,84x
Capitalization 10 677 M
More Financials
Company
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.Its product portfolio includes: XYREM, ERWINAZETM, PRIALT,... 
Sector
Pharmaceuticals
Calendar
08/02 | 11:30amShareholder meeting
More about the company
Surperformance© ratings of Jazz Pharmaceuticals PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on JAZZ PHARMACEUTICALS PLC
07/19JAZZ PHARMACEUTICALS : Journal of Clinical Oncology publishes pivotal Phase 3 da..
PU
07/18Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Oth..
AC
06/29JAZZ PHARMACEUTICALS : Enters Into Agreement with TerSera Therapeutics LLC for P..
PR
06/29JAZZ PHARMACEUTICALS : Vyxeos™ Receives Positive CHMP Opinion for Treatmen..
PU
06/27JAZZ PHARMACEUTICALS : Announces FDA Acceptance of Supplemental New Drug Applica..
PU
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/06JAZZ PHARMACEUTICALS : to Present at the Goldman Sachs Global Healthcare Confere..
PR
06/03JAZZ PHARMACEUTICALS : Presents Long-Term Safety and Efficacy Data from Phase 3 ..
PU
06/03JAZZ PHARMACEUTICALS : Presents Long-Term Safety and Efficacy Data for Xyrem® (s..
PU
05/31JAZZ PHARMACEUTICALS : New Survey Highlights Lack of Awareness of Neurologic Eff..
PU
More news
Sector news : Specialty & Advanced Pharmaceuticals
07/20GLAXOSMITHKLINE : considers splitting up the group - FT
RE
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20GLAXOSMITHKLINE : considers splitting up the group
RE
07/20GLAXOSMITHKLINE : Mulls Separation of Consumer Division -- FT
DJ
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on JAZZ PHARMACEUTICALS PLC 
JAZZ PHARMACEUTICALS - 2013
In an upward trend
BUY
More Strategies
Latest Tweets
07/20Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmace.. 
07/19Jazz Pharmaceuticals PLC $JAZZ CFO Matthew P. Young Sells 700 Shares  
07/19Head to Head Comparison: Takeda Pharmaceutical $TKPYY & Jazz Pharmaceutic.. 
07/18Leerink Swann Lowers Jazz Pharmaceuticals FY2019 Earnings Estimates to $13.92.. 
07/17Jazz Pharmaceuticals $JAZZ Downgraded to “Hold” at BidaskClub  
More tweets
Qtime:183
News from SeekingAlpha
07/19Jazz reports late-stage trial for Vyxeos in blood cancer meets goal 
07/19After Hours Gainers / Losers (7/19/2018) 
07/16The Smart Way To Find Undervalued Stocks 
07/11Premarket analyst action - healthcare 
07/09Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growin.. 
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals PLC Technical Analysis Chart | JAZZ | IE00B4Q5ZN47 | 4-Traders
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 190 $
Spread / Average Target 7,8%
EPS Revisions
Managers
NameTitle
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher President & Chief Operating Officer
Matthew P. Young Chief Financial Officer & Executive Vice President
Paul Treacy Senior Vice President-Technical Operations
Paul L. Berns Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JAZZ PHARMACEUTICALS PLC31.07%10 677
ABBVIE-8.07%142 740
MERCK KGAA-4.36%13 006
KYOWA HAKKO KIRIN CO LTD-2.57%11 111
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD92.33%10 926
CONVATEC GROUP-0.24%5 232